Jang Joonyong, Koo So-My, Kim Ki-Up, Kim Yang-Ki, Uh Soo-Taek, Jang Gae-Eil, Chang Wonho, Lee Bo Young
Department of Internal Medicine, Soonchunhyang University Seoul hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.
Division of Respiratory-Allergy Medicine, Department of Internal Medicine, Soonchunhyang University Seoul hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.
Tuberc Respir Dis (Seoul). 2022 Jul;85(3):249-255. doi: 10.4046/trd.2022.0004. Epub 2022 May 30.
The main cause of death in pulmonary embolism (PE) is right-heart failure due to acute pressure overload. In this sense, extracorporeal membrane oxygenation (ECMO) might be useful in maintaining hemodynamic stability and improving organ perfusion. Some previous studies have reported ECMO as a bridge to reperfusion therapy of PE. However, little is known about the patients that benefit from ECMO.
Patients who underwent ECMO due to pulmonary thromboembolism at a single university-affiliated hospital between January 2010 and December 2018 were retrospectively reviewed.
During the study period, nine patients received ECMO in high-risk PE. The median age of the patients was 60 years (range, 22-76 years), and six (66.7%) were male. All nine patients had cardiac arrests, of which three occurred outside the hospital. All the patients received mechanical support with veno-arterial ECMO, and the median ECMO duration was 1.1 days (range, 0.2-14.0 days). ECMO with anticoagulation alone was performed in six (66.7%), and ECMO with reperfusion therapy was done in three (33.3%). The 30-day mortality rate was 77.8%. The median time taken from the first cardiac arrest to initiation of ECMO was 31 minutes (range, 30-32 minutes) in survivors (n=2) and 65 minutes (range, 33-482 minutes) in non-survivors (n=7).
High-risk PE with cardiac arrest has a high mortality rate despite aggressive management with ECMO and reperfusion therapy. Early decision to start ECMO and its rapid initiation might help save those with cardiac arrest in high-risk PE.
肺栓塞(PE)的主要死亡原因是急性压力过载导致的右心衰竭。从这个意义上讲,体外膜肺氧合(ECMO)可能有助于维持血流动力学稳定并改善器官灌注。先前的一些研究报道了ECMO作为PE再灌注治疗的桥梁。然而,对于从ECMO中获益的患者知之甚少。
回顾性分析2010年1月至2018年12月期间在一家大学附属医院因肺血栓栓塞接受ECMO治疗的患者。
在研究期间,9例高危PE患者接受了ECMO治疗。患者的中位年龄为60岁(范围22 - 76岁),6例(66.7%)为男性。所有9例患者均发生心脏骤停,其中3例发生在院外。所有患者均接受静脉 - 动脉ECMO机械支持,ECMO的中位持续时间为1.1天(范围0.2 - 14.0天)。6例(66.7%)仅接受抗凝的ECMO治疗,3例(33.3%)接受了再灌注治疗的ECMO。30天死亡率为77.8%。幸存者(n = 2)从首次心脏骤停到开始ECMO的中位时间为31分钟(范围30 - 32分钟),非幸存者(n = 7)为65分钟(范围33 - 482分钟)。
尽管对心脏骤停的高危PE进行了积极的ECMO和再灌注治疗,但死亡率仍然很高。早期决定启动ECMO并迅速实施可能有助于挽救心脏骤停的高危PE患者。